Prostate cancer is a malignant tumor that seriously threatens the health of older men. The incidence is low before age 55, increases with age, and in recent years, mortality has declined slightly due to the availability of screening and new drugs.
Generally early prostate cancer has a good prognosis with radical surgery. In some patients who have reached T3 (invasion of the prostate envelope) or T4 (invasion of surrounding tissues, except the seminal vesicles) at the time of detection, or who have lymph nodes or distant metastases, or who are generally in poor physical condition and not suitable for surgical treatment, there are two other modalities, radiation therapy and endocrine therapy.
Endocrine therapy is the most common treatment modality for prostate cancer, including depot therapy, anti-androgen therapy, inhibition of adrenal/prostate derived androgen synthesis, inhibition of testosterone conversion to dihydrotestosterone, and a combination of these treatments. Commonly used drugs include leuprolide, goserelin, enzalutamide, bicalutamide, abiraterone, etc. If there are bone metastases from prostate cancer, the right way out can be used such as diphosphonates and surgical resection.